Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions. Incyte also markets medicines including Pemazyre for certain cancers and Monjuvi in the United States, in partnership with MorphoSys, for a type of lymphoma.

Incyte continues to develop medicines across its therapeutic areas through internal research and collaborations. Hervé Hoppenot serves as the company’s chief executive officer.

Key Stats

• Today's Range: $119.72 to $122.07
• 50-Day Range: $108.62 to $127.62
• 52-Week Range: $89.25 to $132.60
• Volume: 950,394 shs
• Average Volume: 1.73 million shs
• Market Capitalization: $24.66 billion
• P/E Ratio: 64.35
• Dividend Yield: N/A
• Price Target: $132.86
• Consensus Rating: Hold

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 58% of companies evaluated by MarketBeat, and ranked 425th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Incyte has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 11 buy ratings, 13 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Incyte is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Incyte has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 254.46%

Earnings Growth

Earnings for Incyte are expected to grow by 254.46% in the coming year, from $2.24 to $7.94 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 64.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.42.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 64.37, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.62.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 4.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.23% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 5.58.

Change versus previous month

Short interest in Incyte has recently increased by 6.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.50

News Sentiment

Incyte has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Incyte this week, compared to 9 articles on an average week.

Search Interest

29 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 81% compared to the previous 30 days.

MarketBeat Follows

11 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,162,968.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• UBS Global Biopharma Conference 2026: 11/17/2026
• Investor update: 12/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,844
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Incyte: $132.86
• High Price Target: $157.00
• Low Price Target: $90.00
• Potential Upside/Downside: +9.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.88
• Trailing P/E Ratio: 64.35
• Forward P/E Ratio: 15.24
• P/E Growth: 4.45
• Net Income: $1.29 billion
• Net Margins: 6.71%
• Pretax Margin: 13.25%
• Return on Equity: 7.92%
• Return on Assets: 6.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.84
• Quick Ratio: 3.75

Sales & Book Value

• Annual Sales: $5.14 billion
• Price / Sales: 4.80
• Cash Flow: $6.12 per share
• Price / Cash Flow: 19.78
• Book Value: $27.68 per share
• Price / Book: 4.37

Miscellaneous

• Outstanding Shares: 203,830,000
• Free Float: 170,811,000
• Market Cap: $24.66 billion
• Optionable: Optionable
• Beta: 0.78